HRP20140789T1 - Postupci primjene protutijela protiv il-5 - Google Patents
Postupci primjene protutijela protiv il-5 Download PDFInfo
- Publication number
- HRP20140789T1 HRP20140789T1 HRP20140789AT HRP20140789T HRP20140789T1 HR P20140789 T1 HRP20140789 T1 HR P20140789T1 HR P20140789A T HRP20140789A T HR P20140789AT HR P20140789 T HRP20140789 T HR P20140789T HR P20140789 T1 HRP20140789 T1 HR P20140789T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- intended
- antibody against
- accordance
- administered
- Prior art date
Links
- 108010002616 Interleukin-5 Proteins 0.000 claims 18
- 230000036470 plasma concentration Effects 0.000 claims 5
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Protutijelo protiv IL-5, namijenjeno upotrebi u smanjivanju broja eozinofila kod čovjeka koji boluje od hipereozinofilnog sindroma, naznačeno time što navedeno protutijelo protiv IL-5 primijeniti na navedenom čovjeku u pripravku koji sadrži navedeno najmanje jedno protutijelo protiv IL-5, gdje navedeno protutijelo protiv IL-5 ima teški lanac koji sadrži SEQ ID NO: 19 i laki lanac koji sadrži SEQ ID NO: 21, te osigurava srednju najveću koncentracija u plazmi navedenog protutijela protiv IL-5 od najmanje 1,03 ± 0,21 µg/ml do 278 629 µg/ml, a vrijednost površine pod krivuljom(0-∞) za navedeno protutijelo protiv IL-5 je najmanje 15,5 ± 2,7 µg×dan/ml do 4361 6168 µg×dan/ml.
2. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je navedena srednja najveća koncentracija u plazmi u rasponu od 12,1 ± 2,4 µg/ml do 278 629 µg/ml i/ili što je navedeni AUC(0-∞) u rasponu od 207 634 µg×dan/ml do 4361 ± 168 µg×dan/ml.
3. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1 ili patentni zahtjev 2, naznačeno time što navedeni pripravak koji sadrži najmanje jedno protutijelo protiv IL-5 treba primijeniti supkutano.
4. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 3, naznačeno time što navedeni pripravak koji sadrži protutijelo treba primijeniti u dozi od 250 mg.
5. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 4, naznačeno time što navedenu supkutanu dozu treba primijeniti jednom do tri puta.
6. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 5, naznačeno time što je srednja koncentracija u plazmi navedenog protutijela 34,1 ± 12,1 µg/ml do 38,2 ± 9,1 µg/ml i/ili što je AUC(0-∞) za navedeno protutijelo 1110 ± 372 µg×dan/ml do 1196 ± 254 µg×dan/ml.
7. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što navedeni pripravak koji sadrži protutijelo treba primijeniti intramuskularno.
8. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 7, naznačeno time što se navedeni pripravak koji sadrži protutijelo primjenjuje u dozi od 250 mg.
9. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 8, naznačeno time što je navedena srednja koncentracija u plazmi navedenog protutijela 46,9 ± 10,6 µg/ml, a AUC(0-∞) za navedeno protutijelo je 1395 ± 348 µg×dan/ml.
10. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što navedeni pripravak koji sadrži protutijelo treba primijeniti intravenski.
11. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 10, naznačeno time što navedeni pripravak koji sadrži protutijelo treba primijeniti u dozi od 250 mg ili u dozi od 750 mg.
12. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 10 ili 11, naznačeno time što se protutijelo primjenjuje infuzijom, u trajanju od otprilike 30 minuta.
13. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 10, naznačeno time što je navedena srednja koncentracija u plazmi navedenog protutijela 109 ± 17,0 µg/ml, a AUC(0-∞) za navedeno protutijelo je 1557 ± 250 µg×dan/ml.
14. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačeno time što navedeno protutijelo ima serumski poluvijek od 16,2 ± 2,1 dan do 21,7 ± 2,8 dana.
15. Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačeno time što se navedeni pripravak koji sadrži protutijelo primjenjuje zajedno sa steroidom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91483307P | 2007-04-30 | 2007-04-30 | |
| US99071507P | 2007-11-28 | 2007-11-28 | |
| PCT/US2008/062015 WO2008134721A1 (en) | 2007-04-30 | 2008-04-30 | Methods for administering anti-il-5 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140789T1 true HRP20140789T1 (hr) | 2014-10-10 |
Family
ID=39926128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140789AT HRP20140789T1 (hr) | 2007-04-30 | 2014-08-20 | Postupci primjene protutijela protiv il-5 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20100086554A1 (hr) |
| EP (4) | EP2152290B1 (hr) |
| JP (6) | JP2010526088A (hr) |
| CY (1) | CY1115456T1 (hr) |
| DK (1) | DK2152290T3 (hr) |
| ES (1) | ES2492943T3 (hr) |
| HR (1) | HRP20140789T1 (hr) |
| LT (1) | LTC2152290I2 (hr) |
| PL (1) | PL2152290T3 (hr) |
| PT (1) | PT2152290E (hr) |
| SI (1) | SI2152290T1 (hr) |
| WO (2) | WO2008134724A2 (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2152290E (pt) * | 2007-04-30 | 2014-09-03 | Glaxosmithkline Llc | Métodos para administrar anticorpos anti-il-5 |
| AU2009228163B2 (en) * | 2008-03-28 | 2012-08-30 | Glaxosmithkline Llc | Methods of treatment |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
| CN105175542B (zh) | 2010-12-16 | 2018-12-18 | 弗·哈夫曼-拉罗切有限公司 | 与th2抑制相关的诊断和治疗 |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
| CA2924873A1 (en) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
| CA2937556A1 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
| CA2977285A1 (en) | 2015-03-16 | 2016-09-22 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
| KR20180037275A (ko) | 2015-08-24 | 2018-04-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 생물제약 조성물 |
| JP7224304B2 (ja) | 2017-05-26 | 2023-02-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 生物医薬組成物および関連の方法 |
| JP7295038B2 (ja) | 2017-06-06 | 2023-06-20 | グラクソスミスクライン エルエルシー | 小児患者のための生物薬剤組成物及び方法 |
| CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业（上海）股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
| JP7418337B2 (ja) | 2018-02-09 | 2024-01-19 | ジェネンテック， インコーポレイテッド | マスト細胞媒介性炎症性疾患の治療法及び診断法 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| WO2023091608A2 (en) * | 2021-11-18 | 2023-05-25 | Memorial Sloan-Kettering Cancer Center | Methods for treating anti-cancer drug-related skin rashes using benralizumab |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8800397D0 (en) * | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US5096704A (en) * | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
| IT1237881B (it) | 1989-12-12 | 1993-06-18 | Fast Spa | Struttura a profilo complesso, applicabile su apparecchi agitatori, per il bloccaggio di barattoli di vernice, aventi coperchi comunque diversificati |
| CA2129445A1 (en) | 1992-02-06 | 1993-08-07 | Chuan-Chu Chou | Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 |
| US6056957A (en) | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US5783184A (en) * | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
| US7399837B2 (en) * | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| CN100391977C (zh) | 1994-12-23 | 2008-06-04 | 史密丝克莱恩比彻姆公司 | 用于治疗il-5介导的疾病的重组il-5拮抗剂 |
| US5696323A (en) * | 1996-06-25 | 1997-12-09 | Alliedsignal, Inc. | Two bar resonant beam Coriolis rate sensor |
| US6248723B1 (en) * | 1997-06-10 | 2001-06-19 | National Jewish Medical And Research Center | Method for treatment of inflammatory disease |
| US5858089A (en) * | 1997-08-26 | 1999-01-12 | Martinovic; Zoran | Corn buttering tool |
| KR20010031363A (ko) * | 1997-10-22 | 2001-04-16 | 젠스 포니카우 | 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도 |
| MXPA04009418A (es) * | 2002-03-29 | 2005-06-08 | Schering Corp | Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos. |
| PT2152290E (pt) * | 2007-04-30 | 2014-09-03 | Glaxosmithkline Llc | Métodos para administrar anticorpos anti-il-5 |
| US20090035216A1 (en) * | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
| JP5035153B2 (ja) * | 2008-07-14 | 2012-09-26 | 市光工業株式会社 | 車両用灯具 |
-
2008
- 2008-04-30 PT PT87471884T patent/PT2152290E/pt unknown
- 2008-04-30 JP JP2010506604A patent/JP2010526088A/ja active Pending
- 2008-04-30 EP EP08747188.4A patent/EP2152290B1/en active Active
- 2008-04-30 EP EP14166504.2A patent/EP2777710A1/en not_active Withdrawn
- 2008-04-30 EP EP13152633.7A patent/EP2606906A1/en not_active Withdrawn
- 2008-04-30 WO PCT/US2008/062019 patent/WO2008134724A2/en active Application Filing
- 2008-04-30 EP EP08780583A patent/EP2152310A4/en not_active Withdrawn
- 2008-04-30 SI SI200831253T patent/SI2152290T1/sl unknown
- 2008-04-30 JP JP2010506602A patent/JP2010526087A/ja not_active Withdrawn
- 2008-04-30 US US12/598,319 patent/US20100086554A1/en not_active Abandoned
- 2008-04-30 DK DK08747188.4T patent/DK2152290T3/da active
- 2008-04-30 PL PL08747188T patent/PL2152290T3/pl unknown
- 2008-04-30 US US12/598,309 patent/US20100086547A1/en not_active Abandoned
- 2008-04-30 ES ES08747188.4T patent/ES2492943T3/es active Active
- 2008-04-30 WO PCT/US2008/062015 patent/WO2008134721A1/en active Application Filing
-
2014
- 2014-08-07 CY CY20141100618T patent/CY1115456T1/el unknown
- 2014-08-20 HR HRP20140789AT patent/HRP20140789T1/hr unknown
- 2014-09-08 JP JP2014182614A patent/JP2015028042A/ja active Pending
-
2015
- 2015-12-10 US US14/965,130 patent/US20160096886A1/en not_active Abandoned
-
2016
- 2016-03-03 LT LTPA2016005C patent/LTC2152290I2/lt unknown
- 2016-09-26 JP JP2016186583A patent/JP2017036296A/ja active Pending
-
2017
- 2017-10-10 US US15/729,019 patent/US20180022799A1/en not_active Abandoned
-
2018
- 2018-06-06 JP JP2018108483A patent/JP2018158934A/ja active Pending
-
2019
- 2019-09-25 JP JP2019174641A patent/JP2020019781A/ja active Pending
- 2019-10-23 US US16/660,972 patent/US20200040073A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2606906A1 (en) | 2013-06-26 |
| EP2152290A1 (en) | 2010-02-17 |
| WO2008134724A2 (en) | 2008-11-06 |
| EP2152290A4 (en) | 2010-06-02 |
| JP2017036296A (ja) | 2017-02-16 |
| PL2152290T3 (pl) | 2014-11-28 |
| CY1115456T1 (el) | 2017-01-04 |
| JP2015028042A (ja) | 2015-02-12 |
| JP2020019781A (ja) | 2020-02-06 |
| LTC2152290I2 (lt) | 2018-12-27 |
| PT2152290E (pt) | 2014-09-03 |
| SI2152290T1 (sl) | 2014-09-30 |
| JP2018158934A (ja) | 2018-10-11 |
| EP2152310A2 (en) | 2010-02-17 |
| US20200040073A1 (en) | 2020-02-06 |
| DK2152290T3 (da) | 2014-08-18 |
| LTPA2016005I1 (lt) | 2018-11-12 |
| US20160096886A1 (en) | 2016-04-07 |
| US20100086554A1 (en) | 2010-04-08 |
| EP2152310A4 (en) | 2010-05-26 |
| EP2777710A1 (en) | 2014-09-17 |
| EP2152290B1 (en) | 2014-06-04 |
| JP2010526088A (ja) | 2010-07-29 |
| US20100086547A1 (en) | 2010-04-08 |
| ES2492943T3 (es) | 2014-09-10 |
| US20180022799A1 (en) | 2018-01-25 |
| WO2008134721A1 (en) | 2008-11-06 |
| JP2010526087A (ja) | 2010-07-29 |
| WO2008134724A3 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140789T1 (hr) | Postupci primjene protutijela protiv il-5 | |
| AU2009324371B2 (en) | Antibody formulation | |
| AU2005249360B2 (en) | Anti-IL-9 antibody formulations and uses thereof | |
| Lyseng-Williamson et al. | Ferric carboxymaltose: a review of its use in iron-deficiency anaemia | |
| JP2017160208A5 (hr) | ||
| SI2918604T1 (en) | Treatment of childhood acute lymphoblastic leukemia | |
| HRP20110198T1 (hr) | Indikacija doziranja progesterona u liječenju traumatske ozljede mozga | |
| RU2010142309A (ru) | Способы лечения псориаза | |
| RU2021137159A (ru) | Стабильные водные составы на основе антител | |
| JP2009544761A5 (hr) | ||
| WO2006112838A1 (en) | Stabilized anti-hepatitis b (hbv) antibody formulations | |
| Pozzilli et al. | Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes | |
| JP2019512012A5 (hr) | ||
| JP2019520316A5 (hr) | ||
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| Koc et al. | Safety and immunogenicity of HBAI 20 Hepatitis B vaccine in healthy naïve and nonresponding adults | |
| Cassano et al. | Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study) | |
| CA2436402A1 (en) | Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies | |
| JP2016503070A5 (hr) | ||
| Sardana et al. | DPT vaccine‐induced lipoatrophy: an observational study | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| Chung et al. | Spontaneous hypoglycemia due to insulin antibody after insulin treatment of diabetic ketoacidosis | |
| Barde et al. | Infliximab then efalizumab, the ‘hit and run’approach does not work | |
| CA2408688A1 (en) | Method to induce the th1 immune response | |
| JP2020531523A5 (hr) |